Your browser doesn't support javascript.
loading
CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury.
Joy, Mary T; Ben Assayag, Einor; Shabashov-Stone, Dalia; Liraz-Zaltsman, Sigal; Mazzitelli, Jose; Arenas, Marcela; Abduljawad, Nora; Kliper, Efrat; Korczyn, Amos D; Thareja, Nikita S; Kesner, Efrat L; Zhou, Miou; Huang, Shan; Silva, Tawnie K; Katz, Noomi; Bornstein, Natan M; Silva, Alcino J; Shohami, Esther; Carmichael, S Thomas.
Afiliação
  • Joy MT; Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.
  • Ben Assayag E; Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Shabashov-Stone D; Department of Pharmacology, The Institute for Drug Research, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Liraz-Zaltsman S; Department of Pharmacology, The Institute for Drug Research, Hebrew University of Jerusalem, Jerusalem, Israel; The Joseph Sagol Neuroscience Center, Sheba Medical Center, Israel; Institute for Health and Medical Professions, Ono Academic College, Kiryat Ono, Israel.
  • Mazzitelli J; Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.
  • Arenas M; Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.
  • Abduljawad N; Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.
  • Kliper E; Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Korczyn AD; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Thareja NS; Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.
  • Kesner EL; Department of Pharmacology, The Institute for Drug Research, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Zhou M; Departments of Neurobiology, Psychiatry and Biobehavioral Sciences, and Psychology, Integrative Center for Learning and Memory and Brain Research Institute, UCLA, Los Angeles, CA 90095, USA.
  • Huang S; Departments of Neurobiology, Psychiatry and Biobehavioral Sciences, and Psychology, Integrative Center for Learning and Memory and Brain Research Institute, UCLA, Los Angeles, CA 90095, USA.
  • Silva TK; Departments of Neurobiology, Psychiatry and Biobehavioral Sciences, and Psychology, Integrative Center for Learning and Memory and Brain Research Institute, UCLA, Los Angeles, CA 90095, USA.
  • Katz N; Institute for Health and Medical Professions, Ono Academic College, Kiryat Ono, Israel.
  • Bornstein NM; Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Silva AJ; Departments of Neurobiology, Psychiatry and Biobehavioral Sciences, and Psychology, Integrative Center for Learning and Memory and Brain Research Institute, UCLA, Los Angeles, CA 90095, USA.
  • Shohami E; Department of Pharmacology, The Institute for Drug Research, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Carmichael ST; Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA. Electronic address: scarmichael@mednet.ucla.edu.
Cell ; 176(5): 1143-1157.e13, 2019 02 21.
Article em En | MEDLINE | ID: mdl-30794775
ABSTRACT
We tested a newly described molecular memory system, CCR5 signaling, for its role in recovery after stroke and traumatic brain injury (TBI). CCR5 is uniquely expressed in cortical neurons after stroke. Post-stroke neuronal knockdown of CCR5 in pre-motor cortex leads to early recovery of motor control. Recovery is associated with preservation of dendritic spines, new patterns of cortical projections to contralateral pre-motor cortex, and upregulation of CREB and DLK signaling. Administration of a clinically utilized FDA-approved CCR5 antagonist, devised for HIV treatment, produces similar effects on motor recovery post stroke and cognitive decline post TBI. Finally, in a large clinical cohort of stroke patients, carriers for a naturally occurring loss-of-function mutation in CCR5 (CCR5-Δ32) exhibited greater recovery of neurological impairments and cognitive function. In summary, CCR5 is a translational target for neural repair in stroke and TBI and the first reported gene associated with enhanced recovery in human stroke.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Receptores CCR5 / Acidente Vascular Cerebral / Lesões Encefálicas Traumáticas Limite: Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Receptores CCR5 / Acidente Vascular Cerebral / Lesões Encefálicas Traumáticas Limite: Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos